BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
2018
Background
The development of molecular techniques to estimate the risk of breast cancer recurrence has been a significant addition to the suite of tools available to pathologists and breast oncologists. It has previously been shown that immunohistochemistry can provide a surrogate measure of tumor recurrence risk, effectively providing a less expensive and more rapid estimate of risk without the need for send-out. However, concordance between gene expression-based and immunohistochemistry-based approaches has been modest, making it difficult to determine when one approach can serve as an adequate substitute for the other. We investigated whether immunohistochemistry-based methods can be augmented to provide a useful therapeutic indicator of risk.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
64
References
1
Citations
NaN
KQI